Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 6/20 | 0.47 |
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1151389 | 1.00 | KLK5 (0.51) | KLK5ITGB3ITGA2BACACBCTSS | |
| SCHEMBL3364787 | 0.90 | KLK5 (0.57) | KLK5ITGB3ITGA2BCTSSCTSK | |
| SCHEMBL13541200 | 0.90 | KLK5 (0.57) | KLK5ITGB3ITGA2BCTSSCTSK | |
| SCHEMBL13538229 | 0.90 | KLK5 (0.57) | KLK5ITGB3ITGA2BCTSSCTSK | |
| SCHEMBL31407761 | 0.89 | ITGB3 (0.61) | ITGB3ITGA2BACACBCTSSCTSK | |
| SCHEMBL29721250 | 0.88 | KLK5 (0.61) | KLK5ITGB3ITGA2BCTSSCTSK | |
| SCHEMBL2294112 | 0.88 | KLK5 (0.61) | KLK5ITGB3ITGA2BCTSSCTSK | |
| SCHEMBL2294118 | 0.88 | KLK5 (0.61) | KLK5ITGB3ITGA2BCTSSCTSK | |
| SCHEMBL29103443 | 0.88 | KLK5 (0.61) | KLK5ITGB3ITGA2BCTSSCTSK | |
| SCHEMBL2293357 | 0.87 | KLK5 (0.52) | KLK5ITGB3ITGA2BCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262364-B1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | VTV THERAPEUTICS LLC (US) | 2016-03-02 | — | — | EP | disclosed |
| US-9120813-B2 | Oxadiazoanthracene compounds for the treatment of diabetes | VTV THERAPEUTICS LLC (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150087640-A1 | Oxadiazoanthracene Compounds for the Treatment of Diabetes | VTV THERAPEUTICS LLC | 2015-03-26 | — | — | US | disclosed |
| US-8933222-B2 | Oxadiazoanthracene compounds for the treatment of diabetes | TRANSTECH PHARMA, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140187769-A1 | Oxadiazoanthracene Compounds for the Treatment of Diabetes | TRANSTECH PHARMA, LLC (US) | 2014-07-03 | — | — | US | disclosed |
| US-8703766-B2 | Oxadiazoanthracene compounds for the treatment of diabetes | TRANSTECH PHARMA, LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130317015-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-8524708-B2 | Oxadiazoanthracene compounds for the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-7906507-B2 | Oxadiazoanthracene compounds for the treatment of diabetes | TRANSTECH PHARMA, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20110039837-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20100324033-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2262364-A2 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TransTech Pharma, Inc (US) | 2010-12-22 | — | — | EP | disclosed |
| US-7790714-B2 | treating non-insulin dependent diabetes comprising administering a glucagon-like peptide receptor modulators such as (S)-2-({(S)-6-benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid | TRANSTECH PHARMA, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100197677-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7727983-B2 | Glucagon-like peptide-1 (GLP-1) receptor modulators such as (S)-2-({(S)-6-Benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid, used as antidiabetic agents; bioavailability | TRANSTECH PHARMA, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20090306063-A1 | Glucagon-like peptide-1 (GLP-1) receptor modulators such as (S)-2-({(S)-6-Benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid, used as antidiabetic agents; bioavailability | TRANS TECH. PHARMA. INC. (US) | 2009-12-10 | — | — | US | disclosed |
| WO-2009111700-A2 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | TRANSTECH PHARMA, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187769-A1 | Oxadiazoanthracene Compounds for the Treatment of Diabetes | GLP1R, INSR, GPR119 | KLK5 2710/4885ITGB3 2363/4885ITGA2B 3135/4885 |
| US-20110039837-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, OTC | KLK5 2061/4885ITGB3 1639/4885ITGA2B 2443/4885 |
| US-20090306063-A1 | Glucagon-like peptide-1 (GLP-1) receptor modulators such as (S)-2-({(S)-6-Benzoyl-3-[4-(3,4-dichloro-benzyloxy)-phenyl]-2-oxo-2,3,5,6,7,8-hexahydro-1H-4-oxa-1,6-diaza-anthracene-7-carbonyl}-amino)-3-(4'-cyano-biphenyl-4-yl)-propionic acid, used as antidiabetic agents; bioavailability | GLP1R, GIPR, GCGR | KLK5 3506/4885ITGB3 2380/4885ITGA2B 2812/4885 |
| US-20100197677-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, OTC | KLK5 2061/4885ITGB3 1639/4885ITGA2B 2443/4885 |
| US-20130317015-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, OTC | KLK5 2202/4885ITGB3 1666/4885ITGA2B 2346/4885 |
| US-20100324033-A1 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES | GLP1R, GPR119, OTC | KLK5 2061/4885ITGB3 1639/4885ITGA2B 2443/4885 |
| US-20150087640-A1 | Oxadiazoanthracene Compounds for the Treatment of Diabetes | GLP1R, GPR119, OTC | KLK5 2202/4885ITGB3 1666/4885ITGA2B 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.